Cardiovascular effects of the tricyclic antidepressants: implications for new research

  • Alexander H. Glassman
  • B. Timothy Walsh
  • Steven P. Roose


In the preceding chapter, Dr Burrows and his colleagues have reviewed the usual cardiovascular effects of tricyclic antidepressants (TCA). We would like now to focus in greater detail on several cardiovascular effects which are clinically important but have, until recently, been poorly understood. The specific effects we will review are the antiarrhythmic properties of tricyclic compounds, their effect on left ventricular performance, and their propensity to produce orthostatic hypotension. We will discuss why these effects have been poorly understood for so long and will review the implications of these effects on the clinical use of TCA and on our understanding of the basic pharmacology of these drugs.


Antiarrhythmic Drug Antiarrhythmic Effect Left Ventricular Performance Systolic Time Interval Tricyclic Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bigger, J. T., Giardina, E. G., Perel, J. M., Kantor, S. and Glassman, A. (1977).Cardiac antiarrhythmic effect of imipramine hydrochloride. New Engl. J. Med.,296, 206–8PubMedCrossRefGoogle Scholar
  2. Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D. and Zarifian, E. (1980). Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science, N. Y., 209, 303–5CrossRefGoogle Scholar
  3. Burckhardt, D., Raeder, E., Müller, V., Imhof, P. and Neubauer, H. (1978). Cardiovascular effects of tricyclic and tetracyclic antidepressants. J. Am. med. Assoc., 239, 213–6CrossRefGoogle Scholar
  4. Burrows, G. D., Vohra, J., Hunt, D., Sloman, J. G., Scoggins, B. A. and Davies, B. (1976). Cardiac effects of different tricyclic antidepressant drugs. Br. J. Psychiat., 129, 335–41CrossRefGoogle Scholar
  5. Giardina, E. G., Bigger, J. T., Jr, Glassman, A. H., Perel, J. M. and Kantor, S. J. (1979). The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation, 60, 1045–52PubMedCrossRefGoogle Scholar
  6. Giardina, E. G. et al., (1981). Ann. Cardiol., submittedGoogle Scholar
  7. Glassman, A. H., Bigger, J. T., Jr, Giardina, E. V., Kantor, S. J., Perel, J. M. and Davies, M. (1979). Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet, i, 468–72CrossRefGoogle Scholar
  8. Hoffman, B. F. and Bigger, J. T., Jr (1971). Antiarrhythmic drugs. In Drill’s Pharmacology in Medicine, 4th edn (ed. J. R. DiPalma), McGraw-Hill, New York, pp. 824–52Google Scholar
  9. Kantor, S. J., Bigger, J. T., Jr, Glassman, A. H. and Macken, D. L. (1975). Imipramine-induced heart block: a longitudinal case study. J. Am. med. Assoc., 231, 1364–6CrossRefGoogle Scholar
  10. Lecrubier, Y., Allilaire, J. F., Puech, A., Simon, P. and Des Lauriers, A. (1980). Yohimbine antagonism of clomipramine-induced orthostatic hypotension. In Abstracts of the 12th CINP Congress, Supplement to Progress in Neuro-Psychopharmacology, An International Research and Review Journal, Pergamon Press, New York, 1980, p. 220Google Scholar
  11. Marshall, R. C, Berger, H. J., Costin, J. C, Freedman, G. S., Wolberg, J., Cohen, L. S., Gottschalk, A. and Zaret, B. L. (1977). Assessment of cardiac performance with quantitative radionuclide angiocardiography. Circulation, 56, 820–9PubMedCrossRefGoogle Scholar
  12. Moccetti, T., Lichtlen, P., Albert, H., Meier, E. and Imbach, P. (1971). Kardiotoxizität der trizyklischen Antidepressiva. Schweiz, med. Wschr., 101,1Google Scholar
  13. Müller, V. and Burckhardt, D. (1974). Die Wirkung tri- und tetrazyklischer Antidepressiva auf Herz und Kreislauf. Schweiz, med. Wschr., 104, 1911–3Google Scholar
  14. Rawling, D. A. and Fozzard, H. A. (1979). Effects of imipramine on cellular electrophysiological properties of cardiac Purkinje fibers. J. Pharmac exp. Ther., 209, 371–5Google Scholar
  15. Roose, S., Glassman, A. H., Siris, S. and Bruno, R. (1980). TCA-induced postural hypotension; comparative studies. Scientific Proceedings of Supplemental Program, American Psychiatric Association, May, 1980Google Scholar
  16. Taylor, D. J. and Braithwaite, R. A. (1978). Cardiac effects of tricyclic antidepressant medication: a preliminary study of nortriptyline. Br. Heart J., 40, 1005–9PubMedPubMedCentralCrossRefGoogle Scholar
  17. U’Prichard, D. C, Greenberg, D. A., Sheehan, P. P. and Snyder, S. H. (1978). Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain. Science, N. Y., 199, 197–8CrossRefGoogle Scholar
  18. Vohra, J., Burrows, G. D., Hunt, D. and Sloman, G. (1975a). The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur. J. Cardiol, 3, 219–27PubMedGoogle Scholar
  19. Vohra, J., Burrows, G. D. and Sloman, G. (1975b). Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust. N.Z. J. Med., 5, 7–11PubMedCrossRefGoogle Scholar
  20. Weld, F. M. and Bigger, J. T., Jr (1980). Electrophysiological effects of imipramine on ovine cardiac Purkinje and ventricular muscle fibers. Circulation Res., 46, 167–75PubMedCrossRefGoogle Scholar
  21. Wilkerson, R. D. (1978). Antiarrhythmic effects of tricyclic antidepressant drugs in ouabain-induced arrhythmias in the dog. J. Pharmac. exp. Ther., 205, 666–74Google Scholar

Copyright information

© The contributors 1981

Authors and Affiliations

  • Alexander H. Glassman
    • 1
  • B. Timothy Walsh
    • 1
  • Steven P. Roose
    • 1
  1. 1.Department of Psychiatry, College of Physicians and Surgeons, Columbia UniversityThe New York State Psychiatric InstituteNew YorkUSA

Personalised recommendations